259 related articles for article (PubMed ID: 30514160)
1. 1,25 Dihydroxyvitamin D3 Enhances the Antifibroid Effects of Ulipristal Acetate in Human Uterine Fibroids.
Ali M; Shahin SM; Sabri NA; Al-Hendy A; Yang Q
Reprod Sci; 2019 Jun; 26(6):812-828. PubMed ID: 30514160
[TBL] [Abstract][Full Text] [Related]
2. Ulipristal acetate decreases transforming growth factor β3 serum and tumor tissue concentrations in patients with uterine fibroids.
Ciebiera M; Włodarczyk M; Wrzosek M; Słabuszewska-Jóźwiak A; Nowicka G; Jakiel G
Fertil Steril; 2018 Mar; 109(3):501-507.e2. PubMed ID: 29525690
[TBL] [Abstract][Full Text] [Related]
3. Ulipristal acetate decreases active TGF-β3 and its canonical signaling in uterine leiomyoma via two novel mechanisms.
Lewis TD; Malik M; Britten J; Parikh T; Cox J; Catherino WH
Fertil Steril; 2019 Apr; 111(4):806-815.e1. PubMed ID: 30871768
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment of uterine fibroids with ulipristal acetate ☆.
Donnez J; Vázquez F; Tomaszewski J; Nouri K; Bouchard P; Fauser BC; Barlow DH; Palacios S; Donnez O; Bestel E; Osterloh I; Loumaye E;
Fertil Steril; 2014 Jun; 101(6):1565-73.e1-18. PubMed ID: 24630081
[TBL] [Abstract][Full Text] [Related]
5. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E
Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604
[TBL] [Abstract][Full Text] [Related]
6. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
Szamatowicz M; Kotarski J
Ginekol Pol; 2013 Mar; 84(3):219-22. PubMed ID: 23700851
[TBL] [Abstract][Full Text] [Related]
7. EC313-a tissue selective SPRM reduces the growth and proliferation of uterine fibroids in a human uterine fibroid tissue xenograft model.
Nair HB; Santhamma B; Dileep KV; Binkley P; Acosta K; Zhang KYJ; Schenken R; Nickisch K
Sci Rep; 2019 Nov; 9(1):17279. PubMed ID: 31754172
[TBL] [Abstract][Full Text] [Related]
8. Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate.
Yun BS; Seong SJ; Jung YW; Kim ML; Bae HS; Kim MK; Shim SS
Eur J Obstet Gynecol Reprod Biol; 2018 May; 224():133-136. PubMed ID: 29602142
[TBL] [Abstract][Full Text] [Related]
9. Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids.
Tafi E; Scala C; Leone Roberti Maggiore U; Bizzarri N; Candiani M; Venturini PL; Ferrero S
Expert Opin Drug Saf; 2015 Jun; 14(6):965-77. PubMed ID: 25772793
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids.
Ferrero S; Vellone VG; Barra F
Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):107-116. PubMed ID: 29250979
[TBL] [Abstract][Full Text] [Related]
11. Ulipristal Acetate and Extracellular Matrix Production in Human Leiomyomas In Vivo: A Laboratory Analysis of a Randomized Placebo Controlled Trial.
Cox J; Malik M; Britten J; Lewis T; Catherino WH
Reprod Sci; 2018 Feb; 25(2):198-206. PubMed ID: 28929861
[TBL] [Abstract][Full Text] [Related]
12. Ulipristal acetate for uterine fibroids: 2 years of real world experience in a UK hospital.
Woodhead N; Pounds R; Irani S; Pradhan P
J Obstet Gynaecol; 2018 Aug; 38(6):813-817. PubMed ID: 29526144
[TBL] [Abstract][Full Text] [Related]
13. Application of ulipristal acetate in female patients with uterine fibroids.
Grzechocinska B; Gadomska H; Zygula A; Wielgos M
Neuro Endocrinol Lett; 2014; 35(3):175-8. PubMed ID: 24977963
[TBL] [Abstract][Full Text] [Related]
14. Potential synergism between ulipristal acetate and vitamin D3 in uterine fibroid pharmacotherapy - 2 case studies.
Ciebiera M; Męczekalski B; Łukaszuk K; Jakiel G
Gynecol Endocrinol; 2019 Jun; 35(6):473-477. PubMed ID: 30632825
[TBL] [Abstract][Full Text] [Related]
15. A systematic review and meta-analysis of ulipristal acetate for symptomatic uterine fibroids.
Ghonim M; Magdy R; Sabbour M; Ghonim M; Nabhan A
Int J Gynaecol Obstet; 2019 Aug; 146(2):141-148. PubMed ID: 31127621
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D inhibits proliferation of human uterine leiomyoma cells via catechol-O-methyltransferase.
Sharan C; Halder SK; Thota C; Jaleel T; Nair S; Al-Hendy A
Fertil Steril; 2011 Jan; 95(1):247-53. PubMed ID: 20736132
[TBL] [Abstract][Full Text] [Related]
17. Differences in fibroid vascularity after three months of pre-treatment with leuprolide acetate or ulipristal acetate: A pilot study.
Frijlingh M; De Milliano I; Hehenkamp WJK; Huirne JAF
Eur J Obstet Gynecol Reprod Biol; 2020 Feb; 245():186-192. PubMed ID: 31679806
[TBL] [Abstract][Full Text] [Related]
18. 1,25-Dihydroxyvitamin D3 reduces TGF-beta3-induced fibrosis-related gene expression in human uterine leiomyoma cells.
Halder SK; Goodwin JS; Al-Hendy A
J Clin Endocrinol Metab; 2011 Apr; 96(4):E754-62. PubMed ID: 21289245
[TBL] [Abstract][Full Text] [Related]
19. The Biological Impact of Ulipristal Acetate on Cellular Networks Regulating Uterine Leiomyoma Growth.
Tinelli A; Kosmas IP; Mynbaev OA; Malvasi A; Sparic R; Vergara D
Curr Pharm Des; 2020; 26(3):310-317. PubMed ID: 31987017
[TBL] [Abstract][Full Text] [Related]
20. Ulipristal acetate induces cell cycle delay and remodeling of extracellular matrix.
Shin SJ; Kim J; Lee S; Baek J; Lee JE; Cho C; Ha E
Int J Mol Med; 2018 Oct; 42(4):1857-1864. PubMed ID: 30015921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
